The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > BUSINESS
BUSINESS
- Kowa Looks to Triple Eye Drug Business with Glanatec
November 11, 2014
- Germany Designates Eisai’s Antiepileptic Drug Fycompa as Reference Price Drug
November 11, 2014
- AstraZeneca Taps Foreign Doctors to Speak on Forxiga Use Abroad
November 11, 2014
- Nichi-Iko Aims for 300 Million Yen Second Half Sales for Generics Launched in December
November 10, 2014
- Takeda Files Suit in US Claiming Infringement of Its Patents for Gout Treatment Colcrys
November 10, 2014
- MTPC, J&J Collaborate to Promote Educational Activities for Diabetes
November 10, 2014
- Feburic Grabs Top Slot for GP Market in September “Mind Share” Ranking
November 10, 2014
- Meiji Seika Pharma Poised to Get Lion’s Share in Antidepressant Market
November 10, 2014
- Bayer, Kyoto Univ. to Hold First Collaborative Meeting by March
November 7, 2014
- Sales of Four Major Wholesalers Hit by Drop in Long-Listed Product Sales
November 7, 2014
- Ono to Copromote Opdivo with Bristol-Myers in Japan: President
November 7, 2014
- Trebananib Fails to Demonstrate Improvement in OS in PIII Study for Recurrent Ovarian Cancer: Takeda
November 7, 2014
- Toray Medical Files Nalfurafine for Pruritus Associated with Chronic Hepatic Disease
November 7, 2014
- Daiichi Sankyo to Cut Japan Jobs to Brace for Olmetec Patent Expiry
November 6, 2014
- Lorcaserin Confirms POC as Potential Smoking Cessation Aid in PII Study in US: Eisai
November 6, 2014
- Alfresa Transfers Part of Shares of Vaccine-Related Subsidiary to 5 Drug Makers
November 6, 2014
- LEO Pharma to Develop JT’s JAK inhibitor for Skin Disorders Outside Japan
November 6, 2014
- Overseas Growth Boosts Combined Sales of Four Major Drug Makers
November 6, 2014
- Sawai Wins Livalo Trademark Suit
November 6, 2014
- Astellas, Dana-Farber Cut Deal on KRAS Inhibitor Development
November 6, 2014
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…